Kezar Life Sciences (NASDAQ: KZR)
Kezar Life Sciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Kezar Life Sciences Company Info
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
News & Analysis
Why Kezar Life Sciences Stock Is Crushing It Today
A positive phase 2 data readout is lighting a fire underneath the biotech's shares today.
Why Kezar Life Sciences Stock Is Soaring Today
The company reported promising results from a phase 2 study.
Why Kezar Life Sciences Is Down Today
The company's public offering of common stock doesn't exactly thrill investors.
Is This Flaming Hot Biotech Stock a Buy?
Kezar Life Sciences just released interim results on its only drug and shares jumped 70%. After the stock has settled, is now the time to buy?
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.